Case report: Intra arterial thrombolysis with iv line can save an acutely ischemic limb

Shirjeel Murtaza Shirjeel Murtaza, Zohaib Sadiq Zohaib Sadiq
{"title":"Case report: Intra arterial thrombolysis with iv line can save an acutely ischemic limb","authors":"Shirjeel Murtaza Shirjeel Murtaza, Zohaib Sadiq Zohaib Sadiq","doi":"10.55958/jcvd.v18i4.125","DOIUrl":null,"url":null,"abstract":"Acute limb ischemia is a limb threatening emergency condition which requires immediate diagnosis, treatment plan and action. \nIn low income countries still the options of catheter directed thrombolysis under imaging is still not a practical option at many centers. We report a case of 60 years old asthmatic female on inhalers with no history of HF, heart disease, IHD, Afib, hypercholesterolemia, stroke, DM, or HTN who presented at 8 pm at our hospital with 2 hours history of sudden onset severe left hand pain with discoloration. Examination showed absent radial and ulnar artery pulsation. Brachial artery pulse was palpable. Blue discoloration of fingers and hand upto mid palm was noted. Muscular power of hand was intact. Mild sensory loss was present on the tips of all digits. The condition was diagnosed as “Immediately threatened acute limb ischemia”. At night the facility of Doppler or CT angiography was not available so a decision was made to proceed with local thrombolysis with Antegrade A line through brachial artery. \nArterial access was gained by usual IV line of 20 gauge (used for intravenous access) and then thrombolysis was started with streptokinase at a dose of 75000 I.U / hour continuous infusion without any bolus. Infusion was planned to continue for 24 hours. \nAfter 12 hours the radial and ulnar artery pulsations were palpable (3+), hand was warm, pain had settled and colour of hand normalized so the infusion was discontinued and further imaging was planned. \nPatient developed weakness of right side of the body and altered sensorium 2 hours after stopping the infusion. Immediate CT brain was done along with the upper limb with contrast. Brain CT turned out to be normal without any intracranial bleed (Figure A). No other significant finding was observed on CT brain. CT angiogram of upper limb showed a large thrombus at 1st part of left subclavian artery. (Figure.1a and b). 2nd and 3rd part of subclavian artery were normal and so was brachial artery and proximal half of radial artery. Only distal half of radial artery showed linear non occlusive thrombus upto bifurcation of distal radial artery in superficial and deep branches (Figure 3). \nWeakness resolved in next 12 hours but slow mentation continued for next 3 days and then completely recovered. \nSubsequent management was continued with statin, aspirin and anticoagulation with enoxaparin. \nAfter removal of the intra-arterial line a hematoma formed due to poor compression at that time extending from cubital fossa to mid forearm. The hematoma settled in next 30 days. Despite the complications the limb was salvaged. \nDISCUSSION \nCurrently catheter directed thrombolysis holds class 1 indication in ACC guidelines (2016) for salvageable acute limb ischemia.1 Various types of hardware are available for catheter directed thrombolysis but in low income populations the cost is a limitation to the access of such equipment. Once access is gained, various regimes are available for thrombolysis. a bolus dose of the thrombolytic agent is given by the catheter followed by continuous infusion of the same agent. Most commonly used and tested agent is tPa. Recommended dose is a bolus of 4 to 10 mg of recombinant tissue plasminogen activator (tPA) at the time of catheter placement.2 The Society of Interventional Radiology recommends weight-based doses of tPA, 0.02 to 0.1 mg/kg/hr3; however, most clinicians use standard doses of 0.5 to 1 mg/hr for low-dose infusions, with the overall maximum dose limit of 40 mg3. High-dose infusions of >1 mg/hr have been used and typically lead to a slightly higher bleeding risk with comparable outcomes and the benefit of shorter infusion times (21.9 hours for high-dose versus 32.7 hours for low-dose infusions).4 \nHowever data on the use of streptokinase is scarce. We considered the continuous infusion dose of streptokinase without any bolus dose. A relatively low dose as compared to recommended doses for pulmonary embolism and prosthetic valve thrombosis was considered. Thus 75000 units per hour were given. The initial results are favorable and appear cost effective. \nThe risk of hemorrhagic stroke with streptokinase infusion is considered to be upto 0.7 %5. Systemic embolization after streptokinase is also a known complication.6 \nThe hemiparesis and slow mentation was attributed to retrograde embolic showering that occurred due to streptokinase since a large thrombus was seen at the subclavian artery. Fortunately there was no residual deficit after 3 days.  Although the subsequent imaging revealed that a large thrombus was present at the origin of subclavian artery, since it was not flow limiting, it was not of much concern as an emergency. Subsequent long term anticoagulation and percutaneous intervention was be planned as an elective procedure after hematoma settles down. \n  \nOne limitation of study is that we don’t have much literature available on streptokinase for catheter directed thrombolysis for comparison. Further trials are required for validation of the dosage of streptokinase for catheter directed thrombolysis especially where prior imaging is not available due to odd time or limited resources. \n  \nCONCLUSION \nWe conclude that in the absence of advanced imaging and therapeutic facilities a limb threatening ischemia can be treated by simple thrombolysis with streptokinase via antegrade intra-arterial access using regular IV catheter. It is better to act timely than to wait for imaging or catheter directed thrombolysis or thrombo-embolectomy even if thrombus extends beyond the expected confines as in this case a large thrombus was also present at Subclavian artery.","PeriodicalId":227176,"journal":{"name":"The Journal of Cardiovascular Diseases","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Cardiovascular Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.55958/jcvd.v18i4.125","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Acute limb ischemia is a limb threatening emergency condition which requires immediate diagnosis, treatment plan and action. In low income countries still the options of catheter directed thrombolysis under imaging is still not a practical option at many centers. We report a case of 60 years old asthmatic female on inhalers with no history of HF, heart disease, IHD, Afib, hypercholesterolemia, stroke, DM, or HTN who presented at 8 pm at our hospital with 2 hours history of sudden onset severe left hand pain with discoloration. Examination showed absent radial and ulnar artery pulsation. Brachial artery pulse was palpable. Blue discoloration of fingers and hand upto mid palm was noted. Muscular power of hand was intact. Mild sensory loss was present on the tips of all digits. The condition was diagnosed as “Immediately threatened acute limb ischemia”. At night the facility of Doppler or CT angiography was not available so a decision was made to proceed with local thrombolysis with Antegrade A line through brachial artery. Arterial access was gained by usual IV line of 20 gauge (used for intravenous access) and then thrombolysis was started with streptokinase at a dose of 75000 I.U / hour continuous infusion without any bolus. Infusion was planned to continue for 24 hours. After 12 hours the radial and ulnar artery pulsations were palpable (3+), hand was warm, pain had settled and colour of hand normalized so the infusion was discontinued and further imaging was planned. Patient developed weakness of right side of the body and altered sensorium 2 hours after stopping the infusion. Immediate CT brain was done along with the upper limb with contrast. Brain CT turned out to be normal without any intracranial bleed (Figure A). No other significant finding was observed on CT brain. CT angiogram of upper limb showed a large thrombus at 1st part of left subclavian artery. (Figure.1a and b). 2nd and 3rd part of subclavian artery were normal and so was brachial artery and proximal half of radial artery. Only distal half of radial artery showed linear non occlusive thrombus upto bifurcation of distal radial artery in superficial and deep branches (Figure 3). Weakness resolved in next 12 hours but slow mentation continued for next 3 days and then completely recovered. Subsequent management was continued with statin, aspirin and anticoagulation with enoxaparin. After removal of the intra-arterial line a hematoma formed due to poor compression at that time extending from cubital fossa to mid forearm. The hematoma settled in next 30 days. Despite the complications the limb was salvaged. DISCUSSION Currently catheter directed thrombolysis holds class 1 indication in ACC guidelines (2016) for salvageable acute limb ischemia.1 Various types of hardware are available for catheter directed thrombolysis but in low income populations the cost is a limitation to the access of such equipment. Once access is gained, various regimes are available for thrombolysis. a bolus dose of the thrombolytic agent is given by the catheter followed by continuous infusion of the same agent. Most commonly used and tested agent is tPa. Recommended dose is a bolus of 4 to 10 mg of recombinant tissue plasminogen activator (tPA) at the time of catheter placement.2 The Society of Interventional Radiology recommends weight-based doses of tPA, 0.02 to 0.1 mg/kg/hr3; however, most clinicians use standard doses of 0.5 to 1 mg/hr for low-dose infusions, with the overall maximum dose limit of 40 mg3. High-dose infusions of >1 mg/hr have been used and typically lead to a slightly higher bleeding risk with comparable outcomes and the benefit of shorter infusion times (21.9 hours for high-dose versus 32.7 hours for low-dose infusions).4 However data on the use of streptokinase is scarce. We considered the continuous infusion dose of streptokinase without any bolus dose. A relatively low dose as compared to recommended doses for pulmonary embolism and prosthetic valve thrombosis was considered. Thus 75000 units per hour were given. The initial results are favorable and appear cost effective. The risk of hemorrhagic stroke with streptokinase infusion is considered to be upto 0.7 %5. Systemic embolization after streptokinase is also a known complication.6 The hemiparesis and slow mentation was attributed to retrograde embolic showering that occurred due to streptokinase since a large thrombus was seen at the subclavian artery. Fortunately there was no residual deficit after 3 days.  Although the subsequent imaging revealed that a large thrombus was present at the origin of subclavian artery, since it was not flow limiting, it was not of much concern as an emergency. Subsequent long term anticoagulation and percutaneous intervention was be planned as an elective procedure after hematoma settles down.   One limitation of study is that we don’t have much literature available on streptokinase for catheter directed thrombolysis for comparison. Further trials are required for validation of the dosage of streptokinase for catheter directed thrombolysis especially where prior imaging is not available due to odd time or limited resources.   CONCLUSION We conclude that in the absence of advanced imaging and therapeutic facilities a limb threatening ischemia can be treated by simple thrombolysis with streptokinase via antegrade intra-arterial access using regular IV catheter. It is better to act timely than to wait for imaging or catheter directed thrombolysis or thrombo-embolectomy even if thrombus extends beyond the expected confines as in this case a large thrombus was also present at Subclavian artery.
病例报告:静脉输注动脉溶栓可挽救急性肢体缺血
急性肢体缺血是一种危及肢体的急症,需要及时诊断、制定治疗方案和采取行动。在低收入国家,在许多中心,在显像下进行导管定向溶栓仍然不是一个实际的选择。我们报告一例使用吸入器的60岁哮喘女性,无HF、心脏病、IHD、Afib、高胆固醇血症、中风、糖尿病或HTN病史,于晚上8点在我院就诊,有2小时突然发作的严重左手疼痛伴变色史。检查显示桡动脉和尺动脉无搏动。肱动脉脉搏可见。注意到手指和手掌中部的蓝色变色。手部肌肉力量完好无损。所有趾尖均有轻度感觉丧失。诊断为“即刻威胁急性肢体缺血”。夜间由于没有多普勒或CT血管造影设备,因此决定采用顺行a线通过肱动脉进行局部溶栓。通过常规的20号静脉滴注线(用于静脉滴注)获得动脉通路,然后用链激酶开始溶栓,剂量为75000 iu / h,连续滴注,不含任何丸。计划持续输注24小时。12小时后,桡动脉和尺动脉搏动可扪及(3+),手部温暖,疼痛消退,手部颜色正常化,因此停止输液并计划进一步成像。停药2小时后,患者出现右侧身体无力和感觉改变。立即行颅脑CT及上肢造影。颅脑CT显示正常,未见颅内出血(图A)。颅脑CT未见其他明显发现。上肢CT血管造影显示左侧锁骨下动脉第1段有大血栓。(图1a、b)锁骨下动脉第2段、第3段正常,臂动脉、桡动脉近半段正常。只有桡动脉远端一半在桡动脉远端浅支和深支分叉处出现线性非闭塞血栓(图3)。接下来的12小时内虚弱消退,但接下来的3天持续缓慢,然后完全恢复。随后继续使用他汀类药物、阿司匹林和依诺肝素抗凝治疗。去除动脉内线后,由于当时压迫不良形成血肿,从肘窝延伸到前臂中部。血肿在接下来的30天内消失了。尽管有并发症,肢体还是保住了。目前,在ACC指南(2016)中,导管定向溶栓治疗可挽救的急性肢体缺血的适应症为1级各种类型的硬件可用于导管定向溶栓,但在低收入人群中,成本是限制这种设备的使用。一旦获得准入,各种方案可用于溶栓。通过导管给予大剂量的溶栓剂,然后连续输注相同的药物。最常用和测试的药剂是tPa。推荐的剂量是在置管时给药4 ~ 10mg重组组织型纤溶酶原激活剂(tPA)介入放射学会推荐基于体重的tPA剂量,0.02 - 0.1 mg/kg/hr3;然而,对于低剂量输注,大多数临床医生使用0.5至1mg /hr的标准剂量,总最大剂量限制为40mg /hr。已使用> 1mg /hr的高剂量输注,通常导致出血风险略高,结果相似,且输注时间较短(高剂量输注21.9小时,而低剂量输注32.7小时)然而,关于链激酶使用的数据很少。我们考虑的是链激酶的连续输注剂量,而不给药。与肺栓塞和人工瓣膜血栓形成的推荐剂量相比,考虑了相对较低的剂量。因此每小时有75000个单位。初步结果是有利的,似乎具有成本效益。链激酶输注引起出血性中风的风险被认为高达0.7% 5。链激酶后全身栓塞也是一种已知的并发症由于在锁骨下动脉发现了一个大的血栓,因此由于链激酶引起的逆行栓塞性阵雨导致了偏瘫和缓慢的精神状态。幸运的是,3天后没有剩余赤字。虽然随后的影像学显示锁骨下动脉起源处有一个大的血栓,但由于它不是血流受限的,所以作为紧急情况不太值得关注。随后的长期抗凝和经皮介入治疗计划作为血肿消退后的选择性手术。研究的一个局限性是我们没有太多关于链激酶用于导管定向溶栓的文献可供比较。 需要进一步的试验来验证链激酶用于导管定向溶栓的剂量,特别是在由于时间奇怪或资源有限而无法获得先前成像的情况下。结论:在没有先进的影像学和治疗设备的情况下,可以通过常规静脉导管顺行动脉溶栓,采用简单的链激酶溶栓治疗肢体缺血。即使血栓超出预期范围,及时采取行动比等待成像或导管溶栓或血栓-栓子切除术要好,如本例在锁骨下动脉也出现了大血栓。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信